In Support of the Dialysis PATIENTS Demonstration Act (PATIENTS Act)

The Dialysis PATIENTS Demonstration Act (PATIENTS Act) proposed Federal legislation will deliver high-quality, integrated care to patients receiving dialysis for the last stage of kidney failure. The bi-partisan proposal would establish an integrated care program where interdisciplinary teams, led by a nephrologist, provide holistic management for all of the patient’s healthcare needs. I believe this is a groundbreaking piece of legislation that could change the way our healthcare system deals with one of the most fragile patient populations.

Fresenius Medical Care North America (FMCNA) has a long history of leading industry change and pushing the standard of care forward to ensure the best possible outcomes for our patients. FMCNA has been at the forefront of exploring value‐based models like the ESRD C-SNP (Chronic Condition Special Needs Plan) and ESCOs (End Stage Renal Disease Seamless Care Organization) that are run by Fresenius Health Plan (FHP). The PATIENTS Act was carefully crafted to incorporate lessons learned from these earlier models, and I believe it will lead to a major shift in how we approach care, not only for people living with end stage renal disease, but for many other patients with complex chronic conditions.

This legislation is critically important to our healthcare system, our industry, and, most importantly, the patients we serve. To learn more, please visit: https://fmcna.com/the-dialysis-patients-demonstration-act/.

Randell (RJ) Correia, PharmD, is the President of FreseniusRx. In this role, Correia oversees the planning and execution of FreseniusRx’s growth strategies at a time when the business and its parent organization, Fresenius Medical Care North America (FMCNA), are actively transitioning to value-based care and achieving demonstrated success in improving patient health and reducing costs to the health care system.